ro glp-1 program How Our Weight Loss Works Innovation on Ro. Results on

Second, although SGLT2i monotherapy has been linked to improvements in fatty liver index and lower risk of MALO in MASLD patients, 12,15,28,29,30 , our findings suggest that adding GLP-1RA to SGLT2i provided additional hepatic benefits, reducing the risk of MALO by 39%

References 1.Nauck MA, et al

Together, these actions create a metabolic environment where weight loss becomes sustainable without constant willpower or severe calorie restriction

Information retrieved from OMIM as of 3/12/2025

Gastroenterology 2011;141:150156 [DOI] [PMC free article] [PubMed] [Google Scholar] 4.Butler PC, Matveyenko AV, Dry S, Bhushan A, Elashoff R

Instruct patients to contact their physician if cholelithiasis or cholecystitis is suspected for appropriate clinical follow-up [see Warnings and Precautions (5.9)]